Researchers Identify Genetic Variants Linked to Variable Responses to Obesity Drugs

Researchers have identified a set of genetic variants associated with varying responses to obesity drugs. The study, published in Nature, examined data from over 1,000 participants in clinical trials for medications such as semaglutide and tirzepatide. These variants, located in genes related to metabolism and appetite regulation, showed correlations with weight loss outcomes.

The analysis revealed that individuals with specific variants experienced up to 20% greater weight reduction compared to those without them. @Nature reported that the variants influence how the body processes the drugs, affecting efficacy. The research used genome-wide association studies to pinpoint these genetic factors.

Participants were drawn from trials conducted between 2018 and 2023, focusing on adults with obesity.

Blood samples provided genetic data, which was cross-referenced with weight loss measurements after 12 months of treatment. The study controlled for variables like age, sex, and baseline BMI to isolate genetic effects. No single variant accounted for all variability, but combinations of three to five variants predicted response differences with 65% accuracy.

@Nature noted that the findings apply primarily to GLP-1 receptor agonists, a class of drugs mimicking hormones that regulate hunger. Further validation is needed in diverse populations.

This discovery could inform future screening for obesity treatments, allowing doctors to tailor prescriptions based on genetic profiles.

Affected individuals include the estimated 650 million adults worldwide with obesity, per World Health Organization data. Next steps involve larger trials to confirm the variants' predictive power and explore gene-drug interactions. The research underscores the importance of pharmacogenomics in chronic conditions.